A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)

Neuro-Oncology

Volumn 16, Issue 1, 2014, Pages 92-102

  Hutterer, Markus ^a,j   Nowosielski, Martha ^a   Haybaeck, Johannes ^d   Embacher, Sabine ^c   Stockhammer, Florian ^l   Gotwald, Thaddäus ^b   Holzner, Bernhard ^b   Capper, David ^m,n   Preusser, Matthias ^b,e   Marosi, Christine ^b,e   Oberndorfer, Stefan ^f,g   Moik, Martin ^h   Buchroithner, Johanna ⁱ   Seiz, Marcel ^b,o   Tuettenberg, Jochen ^o,p   Herrlinger, Ulrich ^q   Wick, Antje ^m   Vajkoczy, Peter ^k   Stockhammer, Günther ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Department of Neuroradiology ^*  (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f KAISER FRANZ JOSEF HOSPITAL   (Austria)

^g Karl Landsteiner Institute for Implementation of Innovative Techniques in Cardiac Surgery   (Austria)

^h PARACELSUS MEDICAL UNIVERSITY   (Austria)

ⁱ KEPLER UNIVERSITY HOSPITAL   (Austria)

^j UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^m UNIVERSITY OF HEIDELBERG   (Germany)

ⁿ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^o UNIVERSITY OF HEIDELBERG   (Germany)

^p SHG Klinikum Idar Oberstein   (Germany)

^q UNIVERSITY HOSPITAL BONN   (Germany)

more..

Author keywords

antitumor activity and safety; glioblastoma; molecular markers; quality of life; sunitinib

Indexed keywords

BEVACIZUMAB; LOMUSTINE; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BRONCHITIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COGNITIVE DEFECT; DEEP VEIN THROMBOSIS; DERMATITIS; DERMATOMYCOSIS; DIARRHEA; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; EPISTAXIS; ERYTHEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GINGIVITIS; GLIOBLASTOMA; HAND FOOT SYNDROME; HEARTBURN; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INSOMNIA; LEUKOPENIA; LOSS OF APPETITE; LUNG EMBOLISM; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTICENTER STUDY; MUSCLE ATROPHY; MUSCLE CRAMP; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUALITY OF LIFE; RASH; SEPSIS; SINUS BRADYCARDIA; SJOEGREN SYNDROME; SKIN BLEEDING; STOMACH PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; VERTIGO; VITREOUS HEMORRHAGE; VOMITING; YOUNG ADULT; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; DRUG ADMINISTRATION; FOLLOW UP; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PYRROLES; SURVIVAL RATE;

EID: 84891527003     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not161     Document Type: Article

References (39)

1. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med. 2002;8(1):17-23
2. von Deimling A, Louis DN, Wiestler OD. Molecular pathways in the formation of gliomas. Glia. 1995;15(3):328-338
3. Li YM, Hall WA. Cell surface receptors in malignant glioma. Neurosurgery. 2011;69(4):980-994
4. Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol. 2003;13(1):52-61
5. Sakamoto KM. Su-11248 Sugen. Curr Opin Investig Drugs. 2004;5(12): 1329-1339
6. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-337
7. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16-24
8. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. Jama. 2006;295(21):2516-2524
9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferonalfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124
10. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24(15): 2325-2331
11. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet. 2006; 368(9544):1329-1338
12. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6): 501-513
13. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1): 83-95
14. Macdonald DR, Cascino TL, Schold SC Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280
15. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376
16. Taphoorn MJ, Claassens L, Aaronson NK, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46(6):1033-1040
17. Hutterer M, Knyazev P, Abate A, et al. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res. 2008;14(1):130-138
18. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10): 997-1003
19. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572-2578
20. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259
21. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30):4722-4729
22. Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer. 2001;37(11):1345-1351
23. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139-144
24. Kreisl TN, Smith P, Sul J, et al. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol. 2013;111(1):41-48
25. Pan E, Yu D, Yue B, et al. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol. 2012;110(1): 111-118
26. Neyns B, Sadones J, Chaskis C, et al. Phase II studyof sunitinibmalate in patients with recurrent high-grade glioma. J Neurooncol. 2011;103(3): 491-501
27. Plotkin S, Supko JG, Curry WT, et al. Intratumoral Concentrations of Sunitinib after oral administration in patients with high grade glioma [abstract]. Neuro-Oncology. 2011;13:(Supplement 3, SNO 2011 abstract number NO-110):iii41-iii68
28. Hegi ME, Diserens AC, Bady P, et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib-A phase II trial. Mol Cancer Ther. 2011;10(6): 1102-1112
29. Zhou Q, Lv H, Mazloom AR, Xu H, Máayan A, Gallo JM. Activation of Alternate Prosurvival Pathways Accounts for Acquired Sunitinib Resistance in U87MG Glioma Xenografts. J Pharmacol Exp Ther. 2012; 343(2):509-519
30. Hygino da Cruz LC Jr., Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and pseudoresponse: Imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol. 2011;32(11):1978-1985
31. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5): 453-461
32. Brandes AA, Franceschi E, Tosoni A, et al. MGMTpromoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26(13):2192-2197
33. Goldlust SA, Cavaliere R, Newton HB, et al. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. J Neurooncol. 2012;107(2):407-411
34. Yarden Y, KuangWJ, Yang-Feng T, et al. Humanproto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987;6(11):3341-3351
35. Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006;9(4): 287-300
36. Gomes AL, Reis-Filho JS, Lopes JM, et al. Molecular alterations of KIT oncogene in gliomas. Cell Oncol. 2007;29(5):399-408
37. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005;438(7070): 937-945
38. Vajkoczy P, Blum S, Lamparter M, et al. Multistep nature of microvascular recruitment of ex vivo-expanded embryonic endothelial progenitor cells during tumor angiogenesis. J Exp Med. 2003;197(12):1755-1765
39. Fang S, Wei J, Pentinmikko N, Leinonen H, Salven P. Generation of Functional Blood Vessels from a Single c-kit+ Adult Vascular Endothelial Stem Cell. PLoS Biol. 2012;10(10):e1001407